Tuesday, March 14, 2017 8:41:39 AM
CPRX - 1.14 Pre-market now at 1.17/1.20
Biocept and Catalyst Pharmaceuticals Collaborate to Provide Liquid Biopsy Testing for Small Cell Lung Cancer to Patients with Lambert Eaton Myasthenic Syndrome (LEMS)
Biocept and Catalyst Pharmaceuticals Collaborate to Provide Liquid Biopsy Testing for Small Cell Lung Cancer to Patients with Lambert Eaton Myasthenic Syndrome (LEMS)
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
